SCHEMBL5511973

SCHEMBL5511973

CCOC(=O)c1nn(COC(=O)c2ccc([N+](=O)[O-])cc2)nc1C(=O)c1cc(OC)c(OC)cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MITF O75030 1/20 0.45
LMNA P02545 3/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
KCNMA1 Q12791 1/20 0.44
MAPT P10636 5/20 0.44
KCNJ1 P48048 1/20 0.43
KCNH2 Q12809 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
ELANE P08246 2/20 0.42
F2 P00734 1/20 0.42
PLAU P00749 1/20 0.42
CTRB1 P17538 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5517814 0.93 LMNA (0.46) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5516394 0.89 MITF (0.43) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5517319 0.88 LMNA (0.46) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5510150 0.88 LMNA (0.46) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5518115 0.87 LMNA (0.47) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5512240 0.86 LMNA (0.45) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5515199 0.85 LMNA (0.46) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5524848 0.85 LMNA (0.45) ALDH1A1SMN1; SMN2MITFLMNACASP3
SCHEMBL5512810 0.84 LMNA (0.48) ALDH1A1SMN1; SMN2LMNACASP3SENP8
SCHEMBL5510138 0.84 LMNA (0.47) ALDH1A1SMN1; SMN2MITFLMNACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 EP disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 ALDH1A1 959/4885SMN1; SMN2 4840/4885MITF 2287/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 ALDH1A1 691/4885SMN1; SMN2 4795/4885MITF 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.